Search results for " monoclonal"

showing 10 items of 807 documents

Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins

1995

Applying immunohistochemical procedures for the detection of eight different cytokeratin (CK) polypeptides and other differentiation markers, we compared the staining patterns of normal cutaneous structures with those of benign adnexal tumors (n = 65). Syringomas exhibited a marker pattern highly reminiscent of that seen in normal dermal eccrine ducts (EMA in peripheral cells, CK 10 in intermediate cells, and CK 6, CK 19, and CEA in luminal cells). Nodular hidradenomas exhibited complex patterns suggesting relationship between tumor cells, including clear cells, and normal secretory coil cells (CK 7, CK 8, CK 19, and EMA); however, dermal-duct and epidermoid differentiation were also detect…

AdenomaPathologymedicine.medical_specialtySkin NeoplasmsHistologyHidradenomaCellular differentiationDermatologyBiologyBinding CompetitiveInner root sheathPathology and Forensic MedicineCytokeratinReference ValuesBiomarkers TumormedicineCarcinomaHumansNeoplasms Basal CellAdenoma Sweat GlandSyringomaMyoepithelial cellAntibodies MonoclonalCell Differentiationmedicine.diseaseCarcinoma Adenoid CysticImmunohistochemistrySweat GlandsStainingEpidermal CellsKeratinsImmunohistochemistryEpidermisJournal of Cutaneous Pathology
researchProduct

Immunoperoxidase Staining of Fine-Needle Aspiration Biopsies of Renal Cell Carcinoma Using Tumor-Specific Monoclonal Antibody

1987

In 30 nephrectomy specimens, fine needle aspiration biopsies (FNAB) were performed both in the tumor and in the macroscopically normal part of the kidney: 18 were well differentiated renal cell carcinoma (RCC), 6 were moderately differentiated RCC, 4 were poorly differentiated RCC, and 2 were oncocytomas. FNAB was also performed in a bone metastasis of RCC. FNAB materials were stained using the immunoperoxidase method with RCC-specific monoclonal antibody and were compared with the staining of frozen sections. In all cases where tumor-antigen expression could be demonstrated in the frozen sections, a FNAB had already proven positive. There were only 2 false-negative cases where sufficient c…

AdenomaPathologymedicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmenturologic and male genital diseasesMonoclonal antibodyImmunoenzyme TechniquesAntigens NeoplasmRenal cell carcinomaBiopsymedicineHumansCarcinoma Renal CellFrozen section proceduremedicine.diagnostic_testImmunoperoxidasebusiness.industryBiopsy NeedleAntibodies Monoclonalmedicine.diseaseKidney Neoplasmsfemale genital diseases and pregnancy complicationsNephrectomyStainingFine-needle aspirationbusinessEuropean Urology
researchProduct

Lack of requirement for CD8+ cells in recovery from and resistance to experimental autoimmune encephalomyelitis.

1995

Abstract Experimental autoimmune encephalomyelitis (EAE) is a model of T-cell mediated autoimmune disease. Active disease is mediated by myelin basic protein specific CD4+T-cells, whose adoptive transfer can also induce passive disease. In the Lewis rat EAE is a transient disease inducing lasting resistance to rechallenge. The mechanisms of recovery and resistance are poorly understood. CD8+suppressor T-cells have mostly been thought to be central, especially in resistance to reinduction of the disease. In this study we showed by complete depletion of CD8+cells that this subset does not influence either recovery or resistance to EAE in the Lewis rat. This was further confirmed by depleting …

Adoptive cell transferEncephalomyelitis Autoimmune Experimentalmedicine.drug_classEncephalomyelitisImmunologyCD4-CD8 RatioCD8-Positive T-LymphocytesMonoclonal antibodyLymphocyte DepletionImmunopathologymedicineImmunology and AllergyAnimalsAutoimmune diseasebiologyExperimental autoimmune encephalomyelitisAntibodies Monoclonalmedicine.diseaseImmunity InnateMyelin basic proteinRatsRats Inbred LewImmunologybiology.proteinFemaleCD8Journal of autoimmunity
researchProduct

Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell tr…

2007

Although thymoglobulin and alemtuzumab are frequently used in hematopoietic stem cell transplantation (HSCT), little is known of their effects on NK cells, which mediate important functions in post-transplantation immunology. In the present study, we determined NK cell death in vitro using propidium iodide and Annexin V. The NK cell activity in 34 patients at day +30 after allogeneic HSCT was assessed using the CD107a assay. Alemtuzumab and thymoglobulin were similarly very potent in inducing NK cell death in vitro. Even in low concentrations (1 microg/ml) the antibodies induced apoptosis and necrosis in a relevant percentage of NK cells (30%). However, the number of tumor reactive (CD107a+…

AdultAdolescentAntibodies Neoplasmmedicine.medical_treatmentApoptosisHematopoietic stem cell transplantationAntibodies Monoclonal HumanizedLymphocyte DepletionNatural killer cellCell Line TumormedicineHumansTransplantation HomologousProgenitor cellAlemtuzumabAgedAntilymphocyte SerumTransplantationCell DeathThymoglobulinbusiness.industryHematopoietic Stem Cell TransplantationAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseKiller Cells NaturalTransplantationmedicine.anatomical_structureGraft-versus-host diseaseImmunologyAlemtuzumabStem cellbusinessImmunosuppressive Agentsmedicine.drugBone Marrow Transplantation
researchProduct

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation an…

2010

Introduction: Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) that has been introduced recently for Behcet's disease (BD) patients who were resistant to standard treatment. The aim of this study was to analyse the functional changes of Vγ9/Vδ2 T lymphocytes in both active and inactive disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity. Methods: We investigated 1) cell expansion, 2) expression of TNFRII receptor, 3) perforin and gamma interferon (IFN) content, 4) release of granzyme A (GrA) and 5) phenotype changes, in vitro and in vivo, in Vγ9/Vδ2 T lymphocytes by means of fluorescence-activated cell sorter …

AdultAdolescentCell SurvivalT cellLymphocyteT-LymphocytesImmunologyGranzymesInterferon-gammaYoung AdultRheumatologyAntigenmedicineImmunology and AllergyHumansReceptors Tumor Necrosis Factor Type IIInterferon gammaCells CulturedAgedCell ProliferationbiologyPerforinBehcet SyndromeAntibodies MonoclonalReceptors Antigen T-Cell gamma-deltaMiddle AgedInfliximabmedicine.anatomical_structurePhenotypeGranzymePerforinAntirheumatic AgentsCase-Control StudiesImmunologybiology.proteinGranzyme ATumor necrosis factor alphaFemalemedicine.drugResearch ArticleArthritis Research & Therapy
researchProduct

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells

2015

Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by imbalanced immune regulatory networks, and MS patient-derived T effector cells are inefficiently suppressed through regulatory T cells (Treg), a phenomenon known as Treg resistance. In the current study we investigated T cell function in MS patients before and after interferon-beta therapy. We compared cytokine profile, responsiveness for Treg-mediated suppression ex vivo and evaluated reactivity of T cells in vivo using a humanized mouse model. We found that CD4+ and CD8+ T cells of therapy-naive MS patients were resistant to Treg-mediated suppression. Treg resistance is associated with an augmented IL-6 product…

AdultAdolescentdiagnosisReceptor expressionT cellchemical and pharmacologic phenomenaMice SCIDAntibodies Monoclonal Humanizedmultiple sclerosisT-Lymphocytes RegulatoryCatalysisArticleInorganic ChemistryTCIRG1lcsh:ChemistryInterleukin 21Young AdultImmune systemCytotoxic T cellMedicineAnimalsHumansIL-2 receptorPhysical and Theoretical ChemistryMolecular BiologyT effector cellslcsh:QH301-705.5SpectroscopyImmunosuppression TherapyInflammationtherapybusiness.industryOrganic Chemistryimmune regulationGeneral MedicineInterferon-betaMiddle AgedReceptors Interleukin-6Computer Science ApplicationsTregmedicine.anatomical_structureAnimals Newbornlcsh:Biology (General)lcsh:QD1-999ImmunologyLeukocytes MononuclearbusinessCD8International Journal of Molecular Sciences
researchProduct

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

2011

To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66 years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies = 3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100 mg/m(2) per day, range 90-130 mg/m(2) per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P = 0·014) and in those responsive to the previous treatment (P=0·…

AdultAged 80 and overMaleAntineoplastic AgentsMiddle AgedLeukemia Lymphocytic Chronic B-CellAntibodies Monoclonal Murine-DerivedTreatment OutcomeDrug Resistance NeoplasmRecurrenceAntineoplastic Combined Chemotherapy ProtocolsNitrogen Mustard CompoundsBendamustine HydrochlorideDrug EvaluationHumanschronic lymphocytic leukemiaFemaleChronic lymphocytic leukemia; bendamustineBendamustinaEpidemiologic MethodsRituximabAged
researchProduct

Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer

2005

Abstract BACKGROUND: Microsatellite instability (MSI) is a biological characteristic of most tumours, being involved in 85% of hereditary non-polyposis colorectal cancer (HNPCC). It also occurs in 10-15% of sporadic colorectal cancers (CRC). HNPCC appears to be caused by germline mutations in mismatch repair (MMR) genes, which are responsible for repairing single base-pair mismatches. MSI is also associated with a better response of CRC to adjuvant chemotherapy with fluoropyrimidines. We investigated any relationship between the MSI status and the TSmRNA expression, the polymorphisms of 5-Fluorouracil (5-FU cellular target, the enzyme thymidylate synthase (TS) and TS expression evaluated by…

AdultAged 80 and overMalePolymorphism GeneticAntibodies MonoclonalThymidylate SynthaseMiddle AgedSettore MED/08 - Anatomia PatologicaImmunohistochemistryGenomic InstabilityHumansFemaleColorectal cancer thymidylate synthase pharmacogenomic microsatellite instability polymorphism molecular therapeutic.RNA Messenger5' Untranslated RegionsColorectal NeoplasmsPromoter Regions GeneticAgedMicrosatellite Repeats
researchProduct

Topographic heterogeneity of amyloid B-protein epitopes in brains with various forms of neuronal ceroid lipofuscinoses suggesting defective processin…

1990

To verify our hypothesis of defective protease inhibitor domains that are encoded by abnormal processing of amyloid precursor protein (APP) in brains of patients with neuronal ceroid lipofuscinoses (NCL), immunohistochemical and cytochemical studies were performed with monoclonal antibodies (mAbs) directed against various domains of APP. For the studies, 22 autopsy brains were used: 12 with different forms of NCL, and 10 control brains. The staining procedure for the avidin-biotin complex (ABC) technique and the postembedding gold-labelled procedure for electron microscopy (EM) were employed. Of all mAbs used for the study, only mAbs generated against amyloid B-protein bound to neural tissu…

AdultAmyloidPathologymedicine.medical_specialtyBatten diseaseAdolescentAmyloidImmunocytochemistryPathology and Forensic MedicineLipofuscinEpitopes03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineNeuronal Ceroid-LipofuscinosesAmyloid precursor proteinmedicineHumansSenile plaquesChildAged030304 developmental biology0303 health sciencesAmyloid beta-PeptidesbiologyAntibodies MonoclonalBrainInfantMiddle Agedmedicine.diseaseImmunohistochemistryMolecular biology3. Good healthChild Preschoolbiology.proteinNeuronal ceroid lipofuscinosisNeurology (clinical)Protein Processing Post-Translational030217 neurology & neurosurgeryImmunostainingActa Neuropathologica
researchProduct

The 9-O-acetylated disialosyl carbohydrate sequence of CDw60 is a marker on activated human B lymphocytes

1998

Gangliosides with a terminal 9-O-acetylated disialosyl group (CDw60 structures) show a restricted surface expression on human leukocytes. Hithereto, they have only been detected on subpopulations of human T lymphocytes. Using the defined CDw60 antibody UM4D4 and two new antibodies with preferential CDw60 activities, F6 and Z17, we demonstrate for the first time that CDw60 is an activation marker on human B lymphocytes. In vitro phorbol ester-stimulated human peripheral blood B lymphocytes as well as in vivo activated tonsillar B lymphocytes became CDw60 positive. CDw60 expression of these cells exceeds that of resting and activated T-lymphocytes.

AdultAntigens Differentiation T-Lymphocytemedicine.drug_classMolecular Sequence DataImmunologyLymphocyte ActivationMonoclonal antibodyStructure-Activity Relationshipchemistry.chemical_compoundAntigenAntigens CDPolysaccharidesIn vivomedicineHumansImmunology and AllergyStructure–activity relationshipB-LymphocytesbiologyAntibodies MonoclonalAcetylationMiddle AgedMolecular biologyIn vitroCarbohydrate SequenceBiochemistrychemistryAcetylationbiology.proteinPhorbolAntibodyBiomarkersImmunology Letters
researchProduct